Travere Therapeutics (NASDAQ:TVTX) Director Jeffrey Meckler Sells 8,000 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Jeffrey Meckler sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $45.00, for a total value of $360,000.00. Following the transaction, the director owned 87,500 shares of the company’s stock, valued at approximately $3,937,500. This trade represents a 8.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Down 0.2%

Shares of TVTX stock opened at $44.70 on Thursday. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61. The firm has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. The stock has a 50 day moving average of $32.59 and a 200-day moving average of $32.83. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The company had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. During the same period in the previous year, the company earned ($0.47) earnings per share. The company’s quarterly revenue was up 55.6% compared to the same quarter last year. On average, equities analysts predict that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Institutional Trading of Travere Therapeutics

Large investors have recently bought and sold shares of the stock. State of Wyoming bought a new stake in Travere Therapeutics in the fourth quarter valued at $37,000. Torren Management LLC bought a new stake in Travere Therapeutics in the fourth quarter valued at $38,000. Comerica Bank grew its position in Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after acquiring an additional 492 shares during the period. Fifth Third Bancorp bought a new stake in Travere Therapeutics in the first quarter valued at $35,000. Finally, Smartleaf Asset Management LLC grew its position in Travere Therapeutics by 69.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after acquiring an additional 487 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TVTX shares. JPMorgan Chase & Co. cut their price target on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, March 25th. Citigroup upped their target price on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research note on Tuesday. TD Cowen upped their target price on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday. Wedbush upped their target price on Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year?over?year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long?term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre?arranged Rule 10b5?1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500?share sale) can create short?term selling pressure or investor concern. Example SEC filing: CEO Form 4

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.